- In September 2024, Elanco Animal Health partnered with the University of Veterinary Medicine Vienna to develop vaccines for feline infectious peritonitis (FIP). This collaboration aims to bring more effective and affordable vaccines to market, particularly in Europe and Asia, where FIP has been a growing concern due to limited vaccine availability
- In October 2024, Boehringer Ingelheim announced the launch of a new canine vaccine line in Latin America. The updated vaccines offer broader protection against diseases such as kennel cough, leptospirosis, and parvovirus, addressing increasing concerns about infectious diseases among pets in urban areas
- In April 2020, Boehringer Ingelheim U.K. collaborated with VetHelpDirect, that offered all U.K. veterinary practices free access to an online video consultation platform for a period of three months during the pandemic
- In September 2020, Applied DNA Sciences Inc. and Evvivax SRL announced their plans to initiate a veterinary clinical trial for LineaDNA vaccine candidates upon receiving approval for the clinical plan from the US Department of Agriculture. The goal of the vaccine trial is to evaluate the vaccine candidate as a strategy for preventing the COVID-19 (a zoonotic disease) infection in companion felines of humans
- In June 2020, Elanco received regulatory clearance for the acquisition of Bayer AG's animal health business
